PCMA has launched a campaign to counter manufacturers' attempts to impede access to biosimilar drugs. The drugmakers are trying to preempt the FDA by creating a patchwork of state laws that will make it difficult for pharmacists to substitute less-expensive biosimilar drugs when appropriate, raising costs for patients and employers.

Related Summaries